Bu sayfada
01INCY fiyat
02Anlık Görüntü
03Grafik
04Hisse bölünmeleri
05Hakkında
06Performans
07Değerleme ve oranlar
14Kazançlar
15Tüm Temeller
16Finansal Tablolar
17Kurumsal Sahipler (13F)
18Aktivistler ve %5+ sahipler
19Şirket yöneticileri
20ETF sahipliği
21Konsensüs
22Akranlar
23Haberler
25İşlem Sinyalleri
26Metriklerim
INCY Incyte Corporation - Common Stock
NASDAQ · Biotechnology · SEC EDGAR'da Görüntüle ↗ kapat Eki 5, 2026 10-K/10-Q Tem 28, 2026
$114,13
· 52 haftalık aralığın %'i
· düşüğün üstünde
· yükseğe
$82,8252 haftanın en düşüğü
$132,6052 haftanın en yükseği
Piyasa Değeri (MRQ)
$22.94B
P/E (TTM)
14.5
Hisse Başına Kâr (TTM)
$7.85
Gelir (TTM)
$5.82B
rozetleriniz
52 Haftlık Aralık
$83–$133
Analist Derecelendirmesi
HOLD
Fiyat Hedefi
$128
P/E
14.5
ROE
30.7%
Net Kâr Marjı
27.7%
Rozet şeridiniz boş — bu sayfada herhangi bir metriği sabitleyin.
INCY Hisse Senedi Özeti Fiyat, piyasa değeri, P/E, EPS, ROE, borç/öz sermaye, 52 haftalık aralık
Fiyat
$114.13
Piyasa Değeri (MRQ)
$22.94B
P/E (TTM)
14.5
Hisse Başına Kâr (TTM)
$7.85
Gelir (TTM)
$5.82B
ROE (TTM)
30.7%
52 Haftlık Aralık
$83–$133
INCY Hisse Senedi Fiyat Grafiği Teknik göstergeler ile günlük OHLCV — kaydır, yakınlaştır ve görünümünüzü özelleştirin
aralık
çubuklar
Çubuk çözünürlüğü seçilen döneme uyum sağlar — bir çubuk için açılış/yüksek/düşük/kapanış değerlerini görmek için grafiğin üzerine gelin.
Hisse bölünmeleri
| Ex-tarihi | Bölünme | Tür |
|---|---|---|
| 01 Eylül 2000 | 2-for-1 | İleri |
| 10 Kasım 1997 | 2-for-1 | İleri |
Incyte Corporation - Common Stock Hakkında Wikipedia'dan şirket genel bakışı
Incyte Corporation is an American multinational pharmaceutical company with headquarters in Wilmington, Delaware. The company currently operates manufacturing and R&D locations in North America, Europe, and Asia.
Incyte Corporation currently develops and manufactures prescription biopharmaceutical medications in multiple therapeutic areas including oncology, inflammation, and autoimmunity.
History
Incyte Corporation was founded by Roy A. Whitfield on April 8, 1991, in Palo Alto, California, as a genomics company. It became a public company in 1993. Subsequently, scientists and chemists were recruited from DuPont to work for Incyte. Incyte moved its headquarters to Delaware, and acquired Maxia Pharmaceuticals in 2003.
In November 2013, Incyte announced its relocation to new headquarters in Wilmington, Delaware, completing the move by the end of 2014. Hervé Hoppenot became CEO in January 2014.
In 2017, the company became part of the S&P 500 Index, which tracks the 500 most widely held U.S. stocks.
In 2015, Incyte established its European headquarters in Geneva, Switzerland, and later moved this headquarters in 2021. The company expanded its Delaware headquarters, including the addition of a research and development facility, in 2022. Incyte acquired Villaris Therapeutics in 2022, and Escient Pharmaceuticals in 2024.
For 2025, the company reported $5.141 billion in revenue, $6.957 billion in assets and $1.286 billion in net income. Incyte is publicly traded on the NASDAQ under the symbol INCY. Incyte now operates out of North America, Asia, and Europe. Bill Meury became CEO in 2025. Meury replaced Hoppenot, who retired after 11 years in the position.
Pharmaceuticals
Incyte Corporation currently has seven marketed and co-marketed pharmaceutical products, including Jakafi (ruxolitinib), Pemazyre (pemigatinib), Monjuvi (tafasitamab-cxix), Opzelura (Ruxolitinib), Tabrecta (capmatinib), Olumiant (Baricitinib), and Iclusig (ponatinib).
In 2013, Novartis acquired Incyte's c-Met inhibitor capmatinib (INC280, INCB028060), which is marketed under the brand name Tabrecta.
As of 2014, the company was developing baricitinib, an oral JAK1 and JAK2 inhibitor drug for rheumatoid arthritis in partnership with Eli Lilly. It gained EU approval in February 2017. In April 2017, the US FDA issued a rejection, citing concerns about dosing and safety. In May 2018, baricitinib was approved in the United States for the treatment of rheumatoid arthritis under the brand name Olumiant.
As of 2016 epacadostat, an indoleamine 2,3-dioxygenase (IDO1) inhibitor, was in development for various cancers and was in combination trials with Merck's pembrolizumab (Keytruda) and Bristol Myers Squibb's nivolumab (Opdivo).
Acquisition history
Incyte has made a total of 3 acquisitions.
Maxia Pharmaceuticals (2003): An early acquisition in Incyte's history, the company purchased Maxia in 2003 for $42 million.
Villaris Therapeutics (2022): This acquisition was valued at approximately $1.4 billion and included an upfront payment along with milestones. It added new assets to Incyte's portfolio for treating vitiligo and other autoimmune conditions.
Escient Pharmaceuticals (2024): In May 2024, Incyte acquired this San Diego-based, clinical-stage company for $750 million. The acquisition provided Incyte with two oral drug candidates for inflammatory diseases, EP262 and EP547.
Kaynak: Wikipedia (İngilizce), CC BY-SA 4.0 · Wikipedia'da Görüntüle ↗
sektörHealthcare
endüstriBiotechnology
çalışanlar2.844
ülkeUS
10 Yıllık Performans Gelir, net kar, marjlar ve EPS trendleri
Gelir$5.14B2016-12-31 → 2025-12-31
Hisse Başına Kâr$6.412016-12-31 → 2025-12-31
Serbest Nakit Akışı·2017-12-31 → 2022-12-31
Net kar marjı27.7%2018-12-31 → 2025-12-31
Değerleme ve Oranlar
Değerleme P/E, P/S, P/B, EV/EBITDA oranları — hisse senedi pahalı mı ucuz mu?
| Metrik | 5 Yıllık trend | INCY | 5Y ort. | Akran Ortalaması | Sonuç |
|---|---|---|---|---|---|
| P/E (TTM) | 14.55Y ort. ≈113.9 | ≈113.9 | 22.0 | Düşük değerli | |
| F/S (TTM) | 3.95Y ort. ≈4.4 | ≈4.4 | 7.3 | Düşük değerli | |
| F/D (MRQ) | 3.65Y ort. ≈4.0 | ≈4.0 | 6.1 | Düşük değerli | |
| Price / Cash Flow (Fiyat / Nakit Akışı) | 16.05Y ort. ≈23.5 | ≈23.5 | 13.9 | Adil değer | |
| Price / Tangible Book (Fiyat / Maddi Defter Değeri) | 4.55Y ort. ≈3.9 | ≈3.9 | · | · |
Akran ortalaması, metrik başına standartlaştırılmış bir temelde hesaplanır ve bu hisse senedi için gösterilen TTM/MRQ temelini her zaman eşleşmeyebilir.
Kârlılık Brüt, faaliyet ve net kâr marjları; ROE, ROA, ROIC
| Metrik | 5 Yıllık trend | INCY | 5Y ort. | Akran Ortalaması | Sonuç |
|---|---|---|---|---|---|
| Faaliyet Kâr Marjı (TTM) | 30.6%5Y ort. ≈16.9% | ≈16.9% | 16.9% | En üst düzey | |
| FAVÖK Marjı (TTM) | 32.2%5Y ort. ≈18.9% | ≈18.9% | 15.8% | En üst düzey | |
| Vergi Öncesi Kar Marjı (TTM) | 33.8%5Y ort. ≈18.6% | ≈18.6% | 9.3% | En üst düzey | |
| Net Kâr Marjı (TTM) | 27.7%5Y ort. ≈16.9% | ≈16.9% | 12.7% | En üst düzey | |
| ROA (TTM) | 23.5%5Y ort. ≈12.5% | ≈12.5% | 6.8% | En üst düzey | |
| ROE (TTM) | 30.7%5Y ort. ≈16.0% | ≈16.0% | 18.7% | En üst düzey | |
| ROIC | 22.7%5Y ort. ≈14.3% | ≈14.3% | 16.4% | En üst düzey |
Finansal Sağlık Borç, likidite, solventlik — bilanço gücü
| Metrik | 5 Yıllık trend | INCY | 5Y ort. | Akran Ortalaması | Sonuç |
|---|---|---|---|---|---|
| Cari Oran (MRQ) | 4.65Y ort. ≈3.1 | ≈3.1 | 3.1 | Güçlü likidite | |
| Quick Ratio (Cari Oran) | 2.05Y ort. ≈2.0 | ≈2.0 | 1.7 | Güçlü likidite |
Büyüme Gelir, EPS ve net gelir büyümesi: YOY, 3 Yıllık CAGR, 5 Yıllık CAGR
| Metrik | 5 Yıllık trend | INCY | 5Y ort. | Akran Ortalaması | Sonuç |
|---|---|---|---|---|---|
| Revenue YoY (Gelir Yıllık Bazda) | 21.2%5Y ort. ≈14.1% | ≈14.1% | · | · | |
| Revenue CAGR 3Y (Gelir 3 Yıllık Bileşik Büyüme Oranı) | 14.8%5Y ort. ≈12.9% | ≈12.9% | · | · | |
| Revenue CAGR 5Y (Gelir 5 Yıllık Bileşik Büyüme Oranı) | 14.0% | · | · | · | |
| EPS YoY (EPS YB) | 4173.3%5Y ort. ≈1022.2% | ≈1022.2% | · | · | |
| Net Income YoY (Net Gelir Yıllık Bazda) | 3845.0%5Y ort. ≈940.4% | ≈940.4% | · | · | |
| EPS CAGR 3Y (EPS Bileşik Yıllık Büyüme Oranı 3Y) | 61.6% | · | · | · | |
| Net Income CAGR 3Y (Net Gelir Bileşik Yıllık Büyüme Oranı 3Y) | 55.7% | · | · | · |
Sermaye Verimliliği Aktif devir hızı, stok devir hızı, alacak devir hızı
| Metrik | 5 Yıllık trend | INCY | 5Y ort. | Akran Ortalaması | Sonuç |
|---|---|---|---|---|---|
| Asset Turnover (Aktif Devir Hızı) | 0.85Y ort. ≈0.7 | ≈0.7 | 0.7 | En üst düzey | |
| Inventory Turnover (Stok Devir Hızı) | 4.75Y ort. ≈5.6 | ≈5.6 | 1.9 | En üst düzey | |
| Revenue / Employee (Çalışan Başına Gelir) | ≈$1.8M | · | · | · |
değer · ≈ 5Y ort. · sektör ortalaması · ortalamaya göre değerlendirme
Kazanç Geçmişi EPS gerçekleşen vs tahmin, sürpriz %, kazanma oranı, bir sonraki kazanç tarihi
Ort. Sürpriz
19.2%
Sonraki Rapor
Eki 26, 2026
| Dönem | Rapor | EPS Gerçek | EPS Tahmin | Sürpriz |
|---|---|---|---|---|
| 30 Haziran 2026 | Tem 27, 2026 | $3.09 | $2.14 | 44.1% |
| 31 Mart 2026 | $1.81 | $1.40 | 29.4% | |
| 31 Aralık 2025 | $1.80 | $1.97 | -8.5% | |
| 30 Eylül 2025 | $2.26 | $1.69 | 33.7% | |
| 30 Haziran 2025 | $1.57 | $1.50 | 4.7% | |
| 31 Mart 2025 | $1.16 | $1.04 | 11.9% |
Tüm Temeller Tüm metrikler yıla göre — gelir tablosu, bilanço, nakit akışı
Gelir Tablosu
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $5.14B | $4.24B | $3.70B | $3.39B | $2.99B | $2.67B | $2.16B | $1.88B | $1.54B | $1.11B | $754M | $511M | |
| Cost of Revenue | $372M | $312M | $255M | $207M | $151M | $131M | $114M | $94M | $79M | $58M | $27M | $3M | |
| R&D Expense | $2.05B | $2.61B | $1.63B | $1.59B | $1.46B | $2.22B | $1.15B | $1.20B | $1.33B | $582M | $480M | $348M | |
| SG&A Expense | $1.38B | $1.24B | $1.16B | $1.00B | $740M | $517M | $469M | $434M | $366M | $303M | $197M | $166M | |
| Operating Expenses | $3.63B | $4.18B | $3.08B | $2.82B | $2.40B | $2.93B | $1.76B | $1.75B | $1.78B | $961M | $703M | $516M | |
| Operating Income | $1.51B | $61M | $621M | $579M | $586M | $-264M | $402M | $129M | $-243M | $145M | $51M | $-5M | |
| Interest Expense | · | · | $3M | $3M | $2M | $2M | $2M | $2M | $7M | $39M | $46M | $47M | |
| Interest Income | $106M | $129M | $158M | $40M | · | · | · | · | · | · | · | · | |
| Other Non-op | $25M | $13M | $14M | $-519.0K | $11M | $23M | $52M | $32M | $17M | · | · | · | |
| Pretax Income | $1.66B | $317M | $834M | $529M | $570M | $-232M | $487M | $115M | $-312M | $107M | $8M | $-49M | |
| Income Tax | $378M | $284M | $237M | $188M | $-378M | $63M | $40M | $6M | $852.0K | $3M | $1M | $-66.0K | |
| Net Income | $1.29B | $33M | $598M | $341M | $949M | $-296M | $447M | $109M | $-313M | $104M | · | · | |
| EPS (Basic) | $6.59 | $0.16 | $2.67 | $1.53 | $4.30 | $-1.36 | $2.08 | $0.52 | $-1.53 | $0.55 | $0.04 | $-0.29 | |
| EPS (Diluted) | $6.41 | $0.15 | $2.65 | $1.52 | $4.27 | $-1.36 | $2.05 | $0.51 | $-1.53 | $0.54 | $0.03 | $-0.29 | |
| Shares (Basic) | 195,204,000 | 207,110,000 | 223,628,000 | 222,004,000 | 220,428,000 | 218,073,000 | 214,913,000 | 212,383,000 | 204,580,000 | 187,873,000 | 179,601,000 | 167,947,000 | |
| Shares (Diluted) | 200,700,000 | 210,530,000 | 225,928,000 | 223,958,000 | 222,074,000 | 218,073,000 | 217,657,000 | 215,635,000 | 204,580,000 | 194,125,000 | 187,302,000 | 167,947,000 | |
| EBITDA | $1.61B | $151M | · | $647M | $644M | $-212M | $457M | $184M | $-192M | · | · | $37M |
Bilanço
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $3.10B | $1.69B | $3.21B | $2.95B | $2.06B | $1.51B | $1.83B | $1.16B | $900M | $652M | $521M | $452M | |
| Short-term Investments | · | · | · | · | · | · | $285M | $274M | $270M | $156M | $186M | $148M | |
| Inventory | $101M | $59M | $63M | $42M | $28M | $16M | $11M | $7M | $6M | $4M | $2M | $358.0K | |
| Prepaid Expense | $318M | $169M | $183M | $167M | $126M | $60M | $44M | $79M | $62M | $33M | $18M | $21M | |
| Current Assets | $5.02B | $3.24B | $4.65B | $4.09B | $3.12B | $2.36B | $2.48B | $1.83B | $1.50B | $994M | $842M | $680M | |
| PP&E (Net) | $731M | $763M | $752M | $739M | $724M | $560M | $378M | $320M | $260M | $168M | $86M | $82M | |
| PP&E (Gross) | $1.11B | $1.09B | $1.02B | $952M | $900M | $704M | $499M | $423M | $334M | $219M | $131M | $116M | |
| Accum. Depreciation | $375M | $328M | $270M | $213M | $176M | $144M | $122M | $103M | $75M | $52M | $45M | $35M | |
| Goodwill | $133M | $156M | $156M | $156M | $156M | $156M | $156M | $156M | $156M | $156M | · | · | |
| Intangibles | · | · | · | · | · | · | · | · | $237M | $270M | $12M | $2M | |
| Other Non-current Assets | $18M | $11M | $52M | $25M | $37M | $39M | $49M | $19M | $2M | $3M | $12M | · | |
| Total Assets | $6.96B | $5.44B | $6.78B | $5.84B | $4.93B | $3.56B | $3.43B | $2.65B | $2.30B | $1.64B | $1.01B | $796M | |
| Accounts Payable | $210M | $197M | $110M | $278M | $172M | $99M | $84M | $104M | $68M | $76M | $30M | $24M | |
| Accrued Liabilities | $1.03B | $1.21B | $936M | $701M | $534M | $378M | $286M | $229M | $199M | $127M | $87M | $62M | |
| Current Liabilities | $1.52B | $1.64B | $1.24B | $1.16B | $854M | $631M | $513M | $425M | $375M | $274M | $168M | $221M | |
| Capital Leases | $15M | $17M | $14M | $14M | $16M | $14M | $12M | · | · | · | · | · | |
| Deferred Tax | · | · | · | · | · | · | · | · | · | · | · | $20M | |
| Other Non-current Liabilities | $165M | $168M | $149M | $99M | $70M | $58M | $40M | $22M | $20M | $13M | $48M | $55M | |
| Total Liabilities | $1.79B | $2.00B | $1.59B | $1.47B | $1.16B | $950M | $828M | $720M | $672M | $1.22B | $836M | $878M | |
| Long-term Debt | · | · | · | · | · | · | · | $19.09B | $27M | $750M | $750M | $841M | |
| Total Debt | · | · | · | · | · | · | · | · | · | · | · | $689M | |
| Common Stock | $198.0K | $193.0K | $224.0K | $223.0K | $221.0K | $219.0K | $216.0K | $213.0K | $211.0K | $189.0K | $187.0K | $171.0K | |
| Retained Earnings | $214M | $-1.07B | $160M | $-437M | $-778M | $-1.73B | $-1.43B | $-1.88B | $-1.99B | $-1.67B | $-1.78B | $-1.79B | |
| AOCI | $25M | $-13M | $13M | $15M | $-19M | $-15M | $-16M | $-10M | $-7M | $-3M | $-809.0K | $2M | |
| Stockholders' Equity | $5.17B | $3.45B | $5.19B | $4.37B | $3.77B | $2.61B | $2.60B | $1.93B | $1.63B | $419M | $171M | $-82M | |
| Liabilities + Equity | $6.96B | $5.44B | $6.78B | $5.84B | $4.93B | $3.56B | $3.43B | $2.65B | $2.30B | $1.64B | $1.01B | $796M | |
| Shares Outstanding | 198,460,009 | 193,434,305 | 224,286,862 | 222,746,719 | 221,084,433 | 219,489,329 | 216,177,830 | 213,274,660 | 211,262,906 | 188,848,752 | 186,650,249 | 170,876,619 |
Nakit Akışı
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $93M | $89M | $83M | $68M | $58M | $52M | $55M | $55M | $52M | $58M | $45M | $41M | |
| Stock-based Comp | $249M | $266M | $216M | $188M | $183M | $178M | $167M | $148M | $133M | $96M | $70M | $62M | |
| Deferred Tax | $248M | $-86M | $-159M | $57M | $-466M | $-350.0K | $-377.0K | $-459.0K | $-805.0K | · | · | · | |
| Amort. of Intangibles | $27M | $24M | $22M | $22M | $22M | $22M | $22M | $22M | $22M | $13M | · | · | |
| Other Non-cash | $-463M | $33M | · | $316M | $26M | $-58M | $43M | $24M | · | · | · | · | |
| Operating Cash Flow | $1.41B | $335M | $496M | $970M | $749M | $-125M | $711M | $336M | $-93M | $305M | $89M | $26M | |
| CapEx | · | · | · | $78M | $181M | $187M | $78M | $73M | $111M | $120M | $26M | $28M | |
| Investing Cash Flow | $-103M | $158M | $-208M | $-79M | $-208M | $-269M | $-87M | $-86M | $-350M | $-232M | $-105M | · | |
| Stock Issued | · | · | · | · | · | · | · | · | $649M | · | · | · | |
| Stock Repurchased | $0 | $2.00B | $0 | $0 | · | · | · | · | · | · | · | · | |
| Net Stock Activity | $0 | $-2.00B | · | · | · | · | · | · | $649M | · | · | · | |
| Financing Cash Flow | $101M | $-2.02B | $-20M | $-794.0K | $6M | $72M | $46M | $15M | $690M | $45M | $85M | · | |
| Net Change in Cash | $1.41B | $-1.53B | $262M | $894M | $544M | $-319M | $669M | $265M | $247M | $117M | $69M | $-19M | |
| Taxes Paid | $212M | $373M | $378M | $136M | $68M | $71M | $34M | $5M | $6M | $927.0K | · | · | |
| Free Cash Flow | · | · | · | $892M | $568M | $-312M | $633M | $263M | $-204M | · | · | $-2M | |
| Levered FCF | · | · | · | $890M | $565M | $-315M | $631M | $261M | $-211M | · | · | $-48M |
Kârlılık
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | 29.5% | 1.5% | · | 17.1% | 19.6% | -9.9% | 18.6% | 6.9% | -15.9% | · | · | -0.94% | |
| Net Margin | 25.0% | 0.77% | · | 10.0% | 31.8% | -11.1% | 20.7% | 5.8% | · | · | · | · | |
| Pretax Margin | 32.4% | 7.5% | · | 15.6% | 19.1% | -8.7% | 22.6% | 6.1% | -20.3% | · | · | -9.5% | |
| EBITDA Margin | 31.3% | 3.5% | · | 19.1% | 21.6% | -7.9% | 21.1% | 9.8% | -12.5% | · | · | 7.2% | |
| ROA | 20.8% | 0.53% | · | 6.3% | 22.3% | -8.5% | 14.7% | 4.4% | · | · | · | · | |
| ROE | 27.6% | 0.99% | · | 7.9% | 27.4% | -11.8% | 17.8% | 5.9% | · | · | · | · | |
| ROIC | 22.7% | 0.18% | · | 8.5% | 25.8% | -12.9% | 14.2% | 6.4% | -15.0% | · | · | -0.79% |
Likidite ve Solventlik
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 3.3 | 2.0 | · | 3.5 | 3.7 | 3.7 | 4.8 | 4.3 | 4.0 | · | · | 3.2 | |
| Quick Ratio | 2.0 | 1.0 | · | 2.6 | 2.4 | 2.4 | 4.1 | 3.4 | 3.1 | · | · | 2.7 | |
| Debt / Equity | · | · | · | · | · | · | · | · | · | · | · | -8.4 | |
| Interest Coverage | · | · | · | 217.3 | 307.0 | -121.3 | 216.7 | 83.7 | -35.3 | · | · | -0.1 |
Verimlilik
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.8 | 0.7 | · | 0.6 | 0.7 | 0.8 | 0.7 | 0.8 | 0.8 | · | · | 0.7 | |
| Inventory Turnover | 4.7 | 5.1 | · | 5.9 | 6.8 | 9.4 | 12.4 | 14.0 | 15.0 | · | · | 7.9 |
Hisse Başına
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $26.04 | $17.82 | · | $19.62 | $17.05 | $11.90 | $12.02 | $9.03 | $7.72 | · | · | · | |
| Revenue / Share | $25.62 | $20.15 | · | $15.16 | $13.45 | $12.23 | $9.92 | $8.73 | $7.51 | · | · | · | |
| Cash Flow / Share | $7.04 | $1.59 | · | $4.33 | $3.37 | $-0.57 | $3.27 | $1.56 | $-0.45 | · | · | · | |
| Cash / Share | $15.61 | $8.73 | · | $13.25 | $9.31 | $6.89 | $8.48 | $5.46 | $4.26 | · | · | · | |
| EPS (TTM) | $6.41 | $0.15 | $2.65 | $1.52 | $4.27 | $-1.36 | $2.05 | $0.51 | $-1.53 | $0.54 | $0.03 | $-0.29 |
Büyüme Oranları
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 21.2% | 14.8% | 8.9% | 13.7% | 12.0% | · | · | · | · | · | · | · | |
| Revenue CAGR 3Y | 14.8% | 12.4% | 11.5% | · | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 14.0% | · | · | · | · | · | · | · | · | · | · | · | |
| EPS YoY | 4173.3% | -94.3% | 74.3% | -64.4% | · | · | · | · | · | · | · | · | |
| EPS CAGR 3Y | 61.6% | -67.2% | · | · | · | · | · | · | · | · | · | · | |
| Net Income YoY | 3845.0% | -94.5% | 75.4% | -64.1% | · | · | · | · | · | · | · | · | |
| Net Income CAGR 3Y | 55.7% | -67.5% | · | · | · | · | · | · | · | · | · | · |
Değerleme (TTM)
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $5.14B | $4.24B | $3.70B | $3.39B | $2.99B | $2.67B | $2.16B | $1.88B | $1.54B | $1.11B | $754M | $511M | |
| Net Income TTM | $1.29B | $33M | $598M | $341M | $949M | $-296M | $447M | $109M | $-313M | $104M | · | · | |
| Market Cap | $19.60B | $13.36B | · | $17.89B | $16.23B | $19.09B | $18.88B | $13.56B | $20.01B | · | · | · | |
| P/E | 15.4 | 460.5 | 23.7 | 52.8 | 17.2 | -64.0 | 42.6 | 124.7 | -61.9 | 185.7 | 3615.0 | -252.1 | |
| P/S | 3.8 | 3.2 | · | 5.3 | 5.4 | 7.2 | 8.7 | 7.2 | 13.0 | · | · | · | |
| P/B | 3.8 | 3.9 | · | 4.1 | 4.3 | 7.3 | 7.3 | 7.0 | 12.3 | · | · | · | |
| P / Tangible Book | 3.9 | 4.1 | 2.8 | 4.2 | 4.5 | 7.8 | · | · | · | · | · | · | |
| P / Cash Flow | 13.9 | 39.8 | · | 18.4 | 21.7 | -153.2 | 26.6 | 40.3 | -215.2 | · | · | · | |
| P / FCF | · | · | · | 20.1 | 28.5 | -61.2 | 29.8 | 51.6 | -98.1 | · | · | · | |
| Earnings Yield | 6.5% | 0.22% | 4.2% | 1.9% | 5.8% | -1.6% | 2.4% | 0.80% | -1.6% | 0.54% | 0.03% | -0.40% |
Gelir Tablosu
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.67B | $1.27B | $1.51B | $1.37B | $1.22B | $1.05B | $1.18B | $1.14B | $1.04B | $881M | $1.01B | $919M | $955M | $809M | $927M | $823M | |
| Cost of Revenue | $105M | $105M | $121M | $99M | $79M | $73M | $88M | $86M | $77M | $61M | $70M | $60M | $68M | $57M | $59M | $55M | |
| R&D Expense | $517M | $516M | $611M | $507M | $495M | $437M | $466M | $573M | $1.14B | $429M | $444M | $376M | $401M | $407M | $501M | $384M | |
| SG&A Expense | $352M | $328M | $390M | $329M | $331M | $326M | $327M | $309M | $306M | $300M | $288M | $268M | $284M | $316M | $273M | $266M | |
| Operating Expenses | $976M | $972M | $1.17B | $922M | $685M | $848M | $877M | $992M | $1.52B | $789M | $826M | $704M | $761M | $784M | $857M | $685M | |
| Operating Income | $698M | $301M | $336M | $444M | $530M | $205M | $302M | $146M | $-478M | $92M | $187M | $215M | $194M | $25M | $70M | $138M | |
| Interest Expense | · | · | · | · | · | · | · | · | · | $430.0K | · | $623.0K | $655.0K | $469.0K | · | $641.0K | |
| Interest Income | $38M | $34M | $31M | $27M | $25M | $23M | $21M | $19M | $41M | $47M | · | · | · | · | · | · | |
| Other Non-op | $6M | $3M | $6M | $4M | $7M | $8M | $2M | $5M | $8M | $-2M | $-108M | $46M | $43M | $33M | $-14M | $12M | |
| Pretax Income | $752M | $344M | $390M | $482M | $558M | $234M | $314M | $157M | $-390M | $236M | $271M | $234M | $278M | $52M | $81M | $149M | |
| Income Tax | $166M | $40M | $91M | $58M | $153M | $76M | $113M | $50M | $55M | $67M | $70M | $63M | $74M | $30M | $52M | $36M | |
| Net Income | $586M | $303M | $299M | $424M | $405M | $158M | $201M | $106M | $-445M | $170M | $201M | $171M | $204M | $22M | $28M | $113M | |
| EPS (Basic) | $2.92 | $1.52 | $1.51 | $2.17 | $2.09 | $0.82 | $0.89 | $0.55 | $-2.04 | $0.76 | $0.90 | $0.76 | $0.91 | $0.10 | $0.12 | $0.51 | |
| EPS (Diluted) | $2.81 | $1.47 | $1.46 | $2.11 | $2.04 | $0.80 | $0.90 | $0.54 | $-2.04 | $0.75 | $0.89 | $0.76 | $0.90 | $0.10 | $0.13 | $0.50 | |
| Shares (Basic) | 200,378,000 | 199,343,000 | · | 195,670,000 | 193,995,000 | 193,712,000 | · | 192,629,000 | 218,175,000 | 224,484,000 | · | 224,078,000 | 223,248,000 | 222,960,000 | · | 222,415,000 | |
| Shares (Diluted) | 208,216,000 | 206,830,000 | · | 201,429,000 | 198,744,000 | 198,197,000 | · | 195,838,000 | 218,175,000 | 227,219,000 | · | 226,167,000 | 225,649,000 | 225,589,000 | · | 224,175,000 | |
| EBITDA | $698M | $325M | · | $444M | $530M | $228M | · | $146M | $-478M | $114M | · | $215M | $194M | $44M | · | $138M |
Bilanço
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $3.98B | $3.46B | $3.10B | $2.46B | $1.95B | $1.94B | $1.69B | $1.30B | $987M | $3.35B | · | $3.23B | $3.13B | $2.82B | · | $2.69B | |
| Inventory | $113M | $116M | $101M | $83M | $83M | $64M | $59M | $70M | $101M | $64M | · | $57M | $36M | $41M | · | $46M | |
| Prepaid Expense | $253M | $301M | $318M | $369M | $296M | $212M | $169M | $205M | $208M | $189M | · | $172M | $167M | $194M | · | $180M | |
| Current Assets | $6.03B | $5.48B | $5.02B | $4.28B | $3.64B | $3.51B | $3.24B | $2.81B | $2.57B | $4.85B | · | $4.40B | $4.26B | $3.97B | · | $3.82B | |
| PP&E (Net) | $709M | $720M | $731M | $799M | $799M | $765M | $763M | $773M | $762M | $720M | · | $733M | $749M | $742M | · | $716M | |
| PP&E (Gross) | $1.11B | $1.11B | $1.11B | $1.16B | $1.14B | $1.11B | $1.09B | $1.09B | $1.06B | $1.00B | · | $986M | $988M | $967M | · | $918M | |
| Accum. Depreciation | $404M | $389M | $375M | $361M | $346M | $344M | $328M | $316M | $298M | $283M | · | $253M | $239M | $226M | · | $202M | |
| Goodwill | $133M | $133M | $133M | $156M | $156M | $156M | $156M | $156M | $156M | $156M | · | $156M | $156M | $156M | · | $156M | |
| Other Non-current Assets | $87M | $24M | $18M | $32M | $33M | $30M | $11M | $40M | $22M | $47M | · | $81M | $32M | $21M | · | $24M | |
| Total Assets | $7.87B | $7.34B | $6.96B | $6.33B | $5.82B | $5.75B | $5.44B | $5.01B | $4.66B | $7.14B | · | $6.39B | $6.21B | $5.80B | · | $5.51B | |
| Accounts Payable | $250M | $229M | $210M | $172M | $241M | $196M | $197M | $179M | $148M | $164M | · | $139M | $156M | $56M | · | $163M | |
| Accrued Liabilities | $870M | $1.09B | $1.03B | $948M | $857M | $1.38B | $1.21B | $1.13B | $1.03B | $1.10B | · | $821M | $811M | $825M | · | $700M | |
| Current Liabilities | $1.31B | $1.49B | $1.52B | $1.34B | $1.28B | $1.72B | $1.64B | $1.50B | $1.34B | $1.40B | · | $1.12B | $1.12B | $1.01B | · | $1.01B | |
| Capital Leases | · | · | $15M | · | · | · | $17M | · | · | · | · | · | · | · | · | · | |
| Other Non-current Liabilities | $125M | $127M | $165M | $171M | $180M | $176M | $168M | $145M | $142M | $151M | · | $133M | $140M | $118M | · | $75M | |
| Total Liabilities | $1.53B | $1.72B | $1.79B | $1.68B | $1.65B | $2.08B | $2.00B | $1.84B | $1.66B | $1.74B | · | $1.46B | $1.47B | $1.34B | · | $1.28B | |
| Common Stock | $201.0K | $200.0K | $198.0K | $196.0K | $194.0K | $193.0K | $193.0K | $192.0K | $191.0K | $224.0K | · | $224.0K | $223.0K | $223.0K | · | $222.0K | |
| Retained Earnings | $1.10B | $517M | $214M | $-86M | $-510M | $-915M | $-1.07B | $-1.27B | $-1.38B | $330M | · | $-41M | $-212M | $-416M | · | $-466M | |
| AOCI | $20M | $22M | $25M | $15M | $13M | $-6M | $-13M | $16M | $-5M | $-6M | · | $23M | $27M | $21M | · | $-29M | |
| Stockholders' Equity | $6.34B | $5.62B | $5.17B | $4.65B | $4.17B | $3.67B | $3.45B | $3.17B | $3.00B | $5.39B | $5.19B | $4.93B | $4.74B | $4.46B | $4.37B | $4.23B | |
| Liabilities + Equity | $7.87B | $7.34B | $6.96B | $6.33B | $5.82B | $5.75B | $5.44B | $5.01B | $4.66B | $7.14B | · | $6.39B | $6.21B | $5.80B | · | $5.51B | |
| Shares Outstanding | 200,977,687 | 199,948,401 | 198,460,009 | 196,130,993 | 194,123,265 | 193,783,446 | 193,434,305 | 192,798,328 | 191,572,449 | 224,533,449 | · | 224,101,839 | 223,338,330 | 223,061,787 | · | 222,454,839 |
Nakit Akışı
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $26M | $24M | $24M | $24M | $23M | $22M | $23M | $23M | $22M | $22M | $22M | $21M | $20M | $19M | $18M | $17M | |
| Stock-based Comp | $67M | $64M | $62M | $62M | $65M | $61M | $72M | $78M | $57M | $60M | $60M | $48M | $55M | $53M | $53M | $45M | |
| Other Non-cash | · | $-22M | · | · | · | $25M | · | · | · | $-32M | · | · | · | $-200M | · | · | |
| Operating Cash Flow | $508M | $369M | $543M | $559M | $45M | $266M | $381M | $311M | $-576M | $219M | $148M | $148M | $307M | $-106M | $284M | $296M | |
| CapEx | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | $28M | |
| Investing Cash Flow | $-52M | $-88M | $-37M | $-47M | $-19M | $1M | $-21M | $38M | $214M | $-73M | $-154M | $-17M | $-7M | $-29M | $-21M | $-28M | |
| Stock Repurchased | · | · | $0 | $0 | · | · | $0 | $103.0K | · | · | $0 | $0 | · | · | · | · | |
| Financing Cash Flow | $65M | $85M | $138M | $-13M | $-11M | $-13M | $20M | $-32M | $-2.00B | $-12M | $346.0K | $-37M | $13M | $4M | $-2M | $-14M | |
| Net Change in Cash | $521M | $363M | $643M | $500M | $13M | $254M | $384M | $317M | $-2.36B | $133M | $-14M | $96M | $310M | $-130M | $261M | $255M | |
| Taxes Paid | $15M | $-9M | $27M | $7M | $177M | $844.0K | $70M | $73M | $227M | $3M | $125M | $116M | $130M | $7M | $20M | $40M |
Kârlılık
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | 41.7% | 23.7% | · | 32.5% | 43.6% | 19.5% | · | 12.8% | -45.8% | 10.4% | · | 23.4% | 20.3% | 3.1% | · | 16.8% | |
| Net Margin | 35.0% | 23.8% | · | 31.1% | 33.3% | 15.0% | · | 9.4% | -42.6% | 19.2% | · | 18.6% | 21.3% | 2.7% | · | 13.7% | |
| Pretax Margin | 44.9% | 27.0% | · | 35.3% | 45.9% | 22.2% | · | 13.8% | -37.3% | 26.8% | · | 25.4% | 29.1% | 6.4% | · | 18.1% | |
| EBITDA Margin | 41.7% | 25.5% | · | 32.5% | 43.6% | 21.6% | · | 12.8% | -45.8% | 12.9% | · | 23.4% | 20.3% | 5.4% | · | 16.8% | |
| ROA | 8.6% | 4.6% | · | 7.5% | 7.7% | 2.5% | · | 1.9% | -8.2% | 2.6% | · | 2.9% | 3.5% | 0.40% | · | 2.3% | |
| ROE | 11.1% | 6.5% | · | 10.8% | 11.3% | 3.5% | · | 2.6% | -11.5% | 3.4% | · | 3.7% | 4.6% | 0.52% | · | 3.1% | |
| ROIC | 8.6% | 4.7% | · | 8.4% | 9.2% | 3.8% | · | 3.1% | -18.2% | 1.2% | · | 3.2% | 3.0% | 0.23% | · | 2.5% |
Likidite ve Solventlik
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 4.6 | 3.7 | · | 3.2 | 2.8 | 2.0 | · | 1.9 | 1.9 | 3.5 | · | 3.9 | 3.8 | 3.9 | · | 3.8 | |
| Quick Ratio | 3.0 | 2.3 | · | 1.8 | 1.5 | 1.1 | · | 0.9 | 0.7 | 2.4 | · | 2.9 | 2.8 | 2.8 | · | 2.7 | |
| Interest Coverage | · | · | · | · | · | · | · | · | · | 213.7 | · | 344.6 | 295.8 | 52.8 | · | 215.9 |
Verimlilik
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.2 | 0.2 | · | 0.2 | 0.2 | 0.2 | · | 0.2 | 0.2 | 0.1 | · | 0.2 | 0.2 | 0.1 | · | 0.2 | |
| Inventory Turnover | 1.1 | 1.2 | · | 1.3 | 0.9 | 1.1 | · | 1.3 | 1.1 | 1.2 | · | 1.2 | 1.5 | 1.5 | · | 1.6 |
Hisse Başına
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $31.57 | $28.12 | · | $23.71 | $21.49 | $18.93 | · | $16.45 | $15.64 | $24.02 | · | $22.01 | $21.23 | $20.01 | · | $19.00 | |
| Revenue / Share | $8.04 | $6.15 | · | $6.78 | $6.12 | $5.31 | · | $5.81 | $4.78 | $3.88 | · | $4.06 | $4.23 | $3.58 | · | $3.67 | |
| Cash Flow / Share | · | $1.79 | · | · | · | $1.34 | · | · | · | $0.96 | · | · | · | $-0.47 | · | · | |
| Cash / Share | $19.82 | $17.31 | · | $12.52 | $10.07 | $10.02 | · | $6.76 | $5.15 | $14.90 | · | $14.40 | $14.02 | $12.65 | · | $12.10 | |
| EPS (TTM) | $7.85 | $7.08 | · | $5.85 | $4.28 | $0.20 | · | $0.14 | $0.36 | $3.30 | · | $1.89 | $1.63 | $1.45 | · | $3.93 |
Değerleme (TTM)
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $5.82B | $5.36B | · | $4.81B | $4.58B | $4.41B | · | $4.08B | $3.86B | $3.77B | · | $3.61B | $3.51B | $3.47B | · | $3.33B | |
| Net Income TTM | $1.61B | $1.43B | · | $1.19B | $871M | $21M | · | $32M | $97M | $745M | · | $425M | $366M | $324M | · | $876M | |
| Market Cap | $22.78B | $18.82B | · | $16.63B | $13.22B | $11.73B | · | $12.74B | $11.61B | $12.79B | · | $12.95B | $13.90B | $16.12B | · | $14.82B | |
| P/E | 14.4 | 13.3 | · | 14.5 | 15.9 | 302.8 | · | 472.1 | 168.4 | 17.3 | · | 30.6 | 38.2 | 49.8 | · | 17.0 | |
| P/S | 3.9 | 3.5 | · | 3.5 | 2.9 | 2.7 | · | 3.1 | 3.0 | 3.4 | · | 3.6 | 4.0 | 4.6 | · | 4.5 | |
| P/B | 3.6 | 3.3 | · | 3.6 | 3.2 | 3.2 | · | 4.0 | 3.9 | 2.4 | · | 2.6 | 2.9 | 3.6 | · | 3.5 | |
| P / Tangible Book | 3.7 | 3.4 | · | 3.7 | 3.3 | 3.3 | · | 4.2 | 4.1 | 2.4 | · | 2.7 | 3.0 | 3.7 | · | 3.6 | |
| P / Cash Flow | · | 51.0 | · | · | · | 44.1 | · | · | · | 58.5 | · | · | · | -152.7 | · | · | |
| Earnings Yield | 6.9% | 7.5% | · | 6.9% | 6.3% | 0.33% | · | 0.21% | 0.59% | 5.8% | · | 3.3% | 2.6% | 2.0% | · | 5.9% |
En son dönem solda · null değerler · olarak gösterilir
Finansal Tablolar Gelir tablosu, bilanço, nakit akışı — yıllık, son 5 yıl
| Metrik | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Gelir | $5.14B | $4.24B | $3.70B | $3.39B | $2.99B |
| Faaliyet Kâr Marjı % | 29.5% | 1.5% | · | 17.1% | 19.6% |
| Net Gelir | $1.29B | $33M | $598M | $341M | $949M |
| Seyreltilmiş Hisse Başı Kâr | $6.41 | $0.15 | $2.65 | $1.52 | $4.27 |
| Metrik | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Cari Oran | 3.3 | 2.0 | · | 3.5 | 3.7 |
| Cari Oran | 2.0 | 1.0 | · | 2.6 | 2.4 |
| Metrik | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Serbest Nakit Akışı | · | · | · | $892M | $568M |
Kurumsal Sahipler (13F) 919 dosya · $24.0B toplam · Tarih itibarıyla 30 Eylül 2026
Çeyreklik SEC Form 13F'lerinde bu hisse senedini tuttuklarını bildiren kurumlar. Yalnızca uzun pozisyonlar; tek bir başvuru sahibi, ayrı opsiyon bacakları için iki kez görünebilir. Büyük dengeleyici alım/satım bacakları genellikle piyasa yapımını veya korunmuş envanteri yansıtır, yönlü bir inancı değil.
Sahipler
919
Tutulan Değer
$24.0B
Yeni pozisyonlar
123
Çıkan pozisyonlar
68
Kurumsal faaliyet — Q2 2026 ve önceki çeyrek
| Yeni pozisyonlar | Çıkan pozisyonlar | Artırıldı | Azaldı | Net hisse senedi değişimi |
|---|---|---|---|---|
| 123 (-4 önceki Ç'ye göre) | 68 (-29 önceki Ç'ye göre) | 356 (+47 önceki Ç'ye göre) | 274 (-17 önceki Ç'ye göre) | +1.4M |
Q1 2026 ile karşılaştırıldı. SEC Form 13F başvuruları, çeyrek sonundan itibaren 45 gün içinde ve geç başvuranlar için kısa bir ek süre içinde tamamlanmalıdır — bu pencere içindeki çeyrekler, en son tam olarak raporlanan çifte tercih edilerek atlanır.
| Kurum | Değer | Hisse senetleri | % izlenen 13F'nin | Tür |
|---|---|---|---|---|
| BAKER BROS. ADVISORS LP | $3.487.217.729 | 30.762.330 | 14,52% | Hisse senetleri |
| BlackRock, Inc. | $2.044.188.907 | 18.032.718 | 8,51% | Hisse senetleri |
| VANGUARD GROUP INC | $1.966.652.336 | 19.911.434 | 8,19% | Hisse senetleri |
| Dodge & Cox | $1.355.482.475 | 11.957.326 | 5,64% | Hisse senetleri |
| VANGUARD CAPITAL MANAGEMENT LLC | $1.249.713.401 | 11.024.289 | 5,20% | Hisse senetleri |
| STATE STREET CORP | $1.102.124.009 | 9.722.336 | 4,59% | Hisse senetleri |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $883.198.076 | 7.791.091 | 3,68% | Hisse senetleri |
| AQR CAPITAL MANAGEMENT LLC | $603.177.347 | 5.320.901 | 2,51% | Hisse senetleri |
| GEODE CAPITAL MANAGEMENT, LLC | $536.515.860 | 4.750.735 | 2,23% | Hisse senetleri |
| Invesco Ltd. | $462.561.060 | 4.080.461 | 1,93% | Hisse senetleri |
| WELLINGTON MANAGEMENT GROUP LLP | $405.321.059 | 3.575.521 | 1,69% | Hisse senetleri |
| RENAISSANCE TECHNOLOGIES LLC | $398.135.284 | 3.512.132 | 1,66% | Hisse senetleri |
| MORGAN STANLEY | $334.226.735 | 2.948.364 | 1,39% | Hisse senetleri |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | $311.168.439 | 2.744.958 | 1,30% | Hisse senetleri |
| Robeco Institutional Asset Management B.V. | $276.795.075 | 2.441.735 | 1,15% | Hisse senetleri |
| GOLDMAN SACHS GROUP INC | $261.383.430 | 2.305.782 | 1,09% | Hisse senetleri |
| DIMENSIONAL FUND ADVISORS LP | $258.591.850 | 2.280.803 | 1,08% | Hisse senetleri |
| TWO SIGMA INVESTMENTS, LP | $227.123.448 | 2.003.559 | 0,95% | Hisse senetleri |
| NORTHERN TRUST CORP | $199.736.467 | 1.761.966 | 0,83% | Hisse senetleri |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $191.854.885 | 1.692.439 | 0,80% | Hisse senetleri |
| Legal & General Group Plc | $182.053.894 | 1.605.980 | 0,76% | Hisse senetleri |
| FIRST TRUST ADVISORS LP | $180.015.041 | 1.587.996 | 0,75% | Hisse senetleri |
| VICTORY CAPITAL MANAGEMENT INC | $167.811.569 | 1.480.342 | 0,70% | Hisse senetleri |
| FMR LLC | $156.637.793 | 1.381.773 | 0,65% | Hisse senetleri |
| Caisse de depot et placement du Quebec | $155.360.220 | 1.370.503 | 0,65% | Hisse senetleri |
| MARSHALL WACE, LLP | $148.519.056 | 1.310.154 | 0,62% | Hisse senetleri |
| HSBC HOLDINGS PLC | $148.336.065 | 1.307.743 | 0,62% | Hisse senetleri |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | $145.030.732 | 1.540.913 | 0,60% | Hisse senetleri |
| DEUTSCHE BANK AG\ | $143.172.320 | 1.262.988 | 0,60% | Hisse senetleri |
| AustralianSuper Pty Ltd | $135.634.220 | 1.196.491 | 0,56% | Hisse senetleri |
| Amundi | $133.934.668 | 1.181.498 | 0,56% | Hisse senetleri |
| ROYAL BANK OF CANADA | $128.327.000 | 1.132.050 | 0,53% | Hisse senetleri |
| NORGES BANK | $126.861.970 | 1.119.107 | 0,53% | Hisse senetleri |
| Bank of New York Mellon Corp | $110.279.448 | 972.825 | 0,46% | Hisse senetleri |
| Man Group plc | $108.025.392 | 952.941 | 0,45% | Hisse senetleri |
| VANGUARD FIDUCIARY TRUST CO | $106.959.694 | 943.540 | 0,45% | Hisse senetleri |
| BNP PARIBAS ASSET MANAGEMENT Holding S.A. | $106.304.813 | 937.763 | 0,44% | Hisse senetleri |
| ARMISTICE CAPITAL, LLC | $102.024.567 | 900.005 | 0,42% | Hisse senetleri |
| PANAGORA ASSET MANAGEMENT INC | $99.970.937 | 881.889 | 0,42% | Hisse senetleri |
| JPMORGAN CHASE & CO | $87.335.467 | 761.690 | 0,36% | Hisse senetleri |
| UBS Group AG | $87.051.865 | 767.924 | 0,36% | Hisse senetleri |
| Sound Shore Management Inc /CT/ | $85.895.479 | 757.723 | 0,36% | Hisse senetleri |
| JACOBS LEVY EQUITY MANAGEMENT, INC | $82.953.901 | 731.774 | 0,35% | Hisse senetleri |
| Gotham Asset Management, LLC | $81.567.621 | 719.545 | 0,34% | Hisse senetleri |
| Pictet Asset Management Holding SA | $81.315.880 | 713.354 | 0,34% | Hisse senetleri |
| BANK OF AMERICA CORP /DE/ | $76.653.013 | 676.191 | 0,32% | Hisse senetleri |
| MACKENZIE FINANCIAL CORP | $71.967.956 | 634.862 | 0,30% | Hisse senetleri |
| CITIGROUP INC | $66.477.819 | 586.431 | 0,28% | Hisse senetleri |
| LOS ANGELES CAPITAL MANAGEMENT LLC | $65.633.852 | 578.986 | 0,27% | Hisse senetleri |
| FRANKLIN RESOURCES INC | $63.330.037 | 558.663 | 0,26% | Hisse senetleri |
Aktivistler ve %5+ sahipler 7 pozisyon
SEC Çizelge 13D dosyalayan yatırımcılar — ihraççı üzerinde nüfuz etme niyetiyle %5'in üzerinde faydalı sahiplik (aktivist hisseler, yönetim kurulu kampanyaları, M&A). Her satır, o başvuru sahibinin pozisyonunun bilinen en son durumunu gösterir.
| Başvuru sahibi | Dosyalandı | Hisse | Durum | Amaç | Başvuru |
|---|---|---|---|---|---|
| Baker Bros. Advisors LP, Baker Bros. Advisors (GP) LLC, Julian C. Baker, Felix J. Baker, FBB2, LLC, FBB3 LLC, FBB Associates ×21 başvurular | 11 Mayıs 2026 | 15,60% | Değişiklik | Pasif yatırım | SEC |
| Incyte Corporation ×3 başvurular | 14 Ağustos 2023 | · | İlk başvuru | Sermaye yapısı | SEC |
| Baker Bros. Advisors, LLC, Julian C. Baker, Felix J. Baker, FBB2, LLC, FBB Associates ×2 başvurular | 15 Haziran 2012 | · | İlk başvuru | · | SEC |
| Julian C. Baker, Felix J. Baker ×12 başvurular | 01 Ekim 2009 | · | İlk başvuru | · | SEC |
| Açıklanmayan raporlama kişisi, Açıklanmayan raporlama kişisi, Açıklanmayan raporlama kişisi, Açıklanmayan raporlama kişisi | 25 Şubat 2004 | · | İlk başvuru | · | SEC |
| Açıklanmayan raporlama kişisi, Açıklanmayan raporlama kişisi, Açıklanmayan raporlama kişisi, Açıklanmayan raporlama kişisi, Açıklanmayan raporlama kişisi, Açıklanmayan raporlama kişisi | 29 Eylül 2003 | · | İlk başvuru | · | SEC |
| Açıklanmayan raporlama kişisi, Açıklanmayan raporlama kişisi, Açıklanmayan raporlama kişisi, Açıklanmayan raporlama kişisi, Açıklanmayan raporlama kişisi, Açıklanmayan raporlama kişisi | 15 Ağustos 2002 | · | İlk başvuru | · | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Şirket yöneticileri 61 içeriden öğrenenler · 34 yöneticiler · 17 yönetim kurulu üyeleri
| İçeriden Öğrenen | Rol | Son işlem | Sahip olunan hisse senetleri | Alımlar 12ay | Satışlar 12ay | Net 12ay |
|---|---|---|---|---|---|---|
| William Meury | Chief Executive Officer | 16 Temmuz 2026 A | 183.129 | 0 | 0 | $0 |
| Suketu Upadhyay | EVP & Chief Financial Officer | 04 Mayıs 2026 A | 26.343 | 0 | 0 | $0 |
| Christiana Stamoulis | EVP & Chief Financial Officer | 15 Temmuz 2025 A | 125.759 | 0 | 0 | $0 |
| David W Gryska | Executive Vice President, CFO | 16 Temmuz 2018 F | 10.235 | 0 | 0 | $0 |
| David C Hastings | Chief Financial Officer | 05 Haziran 2014 M | 8.500 | 0 | 0 | $0 |
| Pablo J Cagnoni | President, Global Head of R&D | 15 Eylül 2026 M | 183.200 | 0 | 9 | $-14.102.143 |
| David H Gardner | EVP, Chief Strategy Officer | 22 Eylül 2026 F | 15.904 | 0 | 0 | $0 |
| Ramitpal K Basi | EVP, Human Resources | 25 Ağustos 2026 F | 10.993 | 0 | 0 | $0 |
| Patrick A Mayes | EVP & Chief Scientific Officer | 05 Ağustos 2026 M | 61.441 | 0 | 15 | $-6.562.989 |
| Lee Heeson | EVP, Head of Incyte Intl | 23 Temmuz 2026 A | 38.041 | 0 | 1 | $-289.017 |
| Michael James Morrissey | EVP, Head of Tech. Operations | 23 Temmuz 2026 A | 34.065 | 0 | 3 | $-5.675.002 |
| Richard A. Hoffman | EVP & General Counsel | 16 Temmuz 2026 A | 16.861 | 0 | 0 | $0 |
| Mohamed Khairie Issa | EVP, Head of U.S. Commercial | 16 Temmuz 2026 A | 71.797 | 0 | 2 | $-1.309.770 |
| Thomas Tray | Principal Accounting Officer | 16 Temmuz 2026 A | 21.699 | 0 | 6 | $-878.953 |
| Steven H Stein | CMO & Head of Late-Stage Dev. | 16 Temmuz 2026 A | 30.916 | 0 | 6 | $-7.856.771 |
| Matteo Trotta | EVP, GM, Dermatology US | 25 Mart 2026 F | 14.882 | 0 | 0 | $0 |
| Sheila A. Denton | EVP & General Counsel | 17 Kasım 2025 M | 26.569 | 0 | 5 | $-465.184 |
| Vijay K Iyengar | EVP, GMAPPS | 16 Temmuz 2025 S | 40.540 | 0 | 0 | $0 |
| Barry P Flannelly | EVP & General Manager US | 16 Temmuz 2025 S | 35.149 | 0 | 0 | $0 |
| Paula J Swain | EVP, Human Resources | 15 Temmuz 2025 A | 106.482 | 0 | 0 | $0 |
| Jonathan Elliott Dickinson | EVP, General Manager, Europe | 12 Eylül 2024 S | 36.390 | 0 | 0 | $0 |
| Dashyant Dhanak | EVP & Chief Scientific Officer | 14 Temmuz 2023 A | 58.968 | 0 | 0 | $0 |
| Maria E Pasquale | EVP & General Counsel | 14 Temmuz 2023 A | 69.724 | 0 | 0 | $0 |
| Paul Trower | Principal Accounting Officer | 19 Ocak 2022 A | 32.268 | 0 | 0 | $0 |
| Yao Wenqing | EVP, Head of Discovery Chem | 02 Temmuz 2021 A | 98.575 | 0 | 0 | $0 |
| Reid M Huber | EVP, Chief Scientific Officer | 16 Temmuz 2018 F | 34.571 | 0 | 0 | $0 |
| Eric H. Siegel | EVP, General Counsel | 13 Eylül 2017 F | 21.053 | 0 | 0 | $0 |
| Richard S Levy | EVP, Chief Drug Dev Officer | 06 Ocak 2016 M | 16.926 | 0 | 0 | $0 |
| James M Daly | EVP, Chief Commercial Officer | 23 Haziran 2015 M | 3.521 | 0 | 0 | $0 |
| Patricia S Andrews | Chief Commercial Officer | 19 Ocak 2012 A | · | 0 | 0 | $0 |
| Patricia A Schreck | EVP, General Counsel | 10 Mayıs 2011 M | 4.500 | 0 | 0 | $0 |
| Brian W Metcalf | Chief Drug Discovery Scientist | 11 Nisan 2011 M | 66.504 | 0 | 0 | $0 |
| Steven M. Friedman | EVP, Biology & Preclinical Dev | 18 Mayıs 2010 A | 38.137 | 0 | 0 | $0 |
| John A Keller | Chief Business Officer | 08 Şubat 2008 A | · | 0 | 0 | $0 |
| Paul J Clancy | Yönetim kurulu üyesi | 30 Eylül 2026 A | 25.838 | 0 | 1 | $-1.423.950 |
| Edmund Harrigan | Yönetim kurulu üyesi | 30 Eylül 2026 A | 23.225 | 0 | 0 | $0 |
| Katherine A High | Yönetim kurulu üyesi | 08 Haziran 2026 A | 14.983 | 0 | 0 | $0 |
| Jacqualyn A Fouse | Yönetim kurulu üyesi | 08 Haziran 2026 A | 20.968 | 0 | 0 | $0 |
| Jean Jacques Bienaime | Yönetim kurulu üyesi | 08 Haziran 2026 A | 24.424 | 0 | 0 | $0 |
| Otis W Brawley | Yönetim kurulu üyesi | 08 Haziran 2026 A | 12.894 | 0 | 0 | $0 |
| Herve Hoppenot | Yönetim kurulu üyesi | 08 Aralık 2025 F | 326.803 | 0 | 1 | $-19.773.750 |
| Susanne Schaffert | Yönetim kurulu üyesi | 10 Haziran 2025 A | 7.389 | 0 | 0 | $0 |
| Wendy L Dixon | Yönetim kurulu üyesi | 31 Mart 2022 A | 17.768 | 0 | 0 | $0 |
| Paul A Friedman, M.D. | Yönetim kurulu üyesi | 26 Mayıs 2020 A | 256.813 | 0 | 0 | $0 |
| Paul A Brooke | Yönetim kurulu üyesi | 31 Mart 2020 A | 221.911 | 0 | 0 | $0 |
| Barry A Ariko | Yönetim kurulu üyesi | 12 Mart 2015 M | 45.834 | 0 | 0 | $0 |
| Richard U De Schutter | Yönetim kurulu üyesi | 05 Mart 2015 M | 92.290 | 0 | 0 | $0 |
| Roy A Whitfield | Yönetim kurulu üyesi | 17 Aralık 2013 M | 666.082 | 0 | 0 | $0 |
| John F Niblack | Yönetim kurulu üyesi | 20 Mayıs 2011 A | · | 0 | 0 | $0 |
| Fred B Craves | Yönetim kurulu üyesi | 01 Haziran 2005 A | 196.793 | 0 | 0 | $0 |
| DAMIAL FOUNDATION INC | 10% sahip | 11 Şubat 2004 S | · | 0 | 0 | $0 |
| Bonnie J Tisch | 10% sahip | 14 Ocak 2004 S | · | 0 | 0 | $0 |
| Laurent Chardonnet | · | 30 Mart 2015 M | 2.905 | 0 | 0 | $0 |
| Julian C. Baker | · | 30 Mayıs 2013 A | 66.340 | 0 | 0 | $0 |
| Matthew Emmens | · | 22 Mayıs 2008 A | · | 0 | 0 | $0 |
| HURLEY SCOTT W | · | 19 Ocak 2005 A | · | 0 | 0 | $0 |
| Daniel R Tisch | · | 12 Ağustos 2004 P | 1.216.661 | 0 | 0 | $0 |
| TISCH THOMAS J | · | 12 Ağustos 2004 P | 1.416.661 | 0 | 0 | $0 |
| James S Tisch | · | 12 Ağustos 2004 P | 1.216.661 | 0 | 0 | $0 |
| Andrew H Tisch | · | 12 Ağustos 2004 P | 1.216.661 | 0 | 0 | $0 |
| Jon S Saxe | · | 30 Mart 2004 M | 80.000 | 0 | 0 | $0 |
SEC Form 3/4/5 başvurularından yöneticiler; net = yalnızca açık piyasa Alış/Satış
ETF sahipliği 149 ETF'ler tarafından tutuluyor
Ağırlık yalnızca doğrudan öz sermaye varlıklarını (N-PORT) yansıtır; kaldıraçlı veya türev tabanlı fonlar gösterilmeyen ek swap pozisyonlarına sahip olabilir.
| Fon | Ağırlık | Birimler | Tarih itibarıyla | Kaynak |
|---|---|---|---|---|
| IDNA · iShares Trust | 3,73% | 77.294 SH | 11 Eylül 2026 | Günlük |
| SAWG · ETF Series Solutions | 3,28% | 792 NS | 31 Temmuz 2026 | N-PORT |
| BUL · Pacer Funds Trust | 3,05% | 33.574 NS | 31 Temmuz 2026 | N-PORT |
| PBE · Invesco Exchange-Traded Fund Trust | 2,55% | 90.459 SH | 02 Ekim 2026 | Günlük |
| SMRI · EA Series Trust | 2,07% | 111.793 NS | 31 Temmuz 2026 | N-PORT |
| FGSI · First Trust Exchange-Traded Fund IV | 1,99% | 344 NS | 31 Temmuz 2026 | N-PORT |
| POWA · Invesco Exchange-Traded Self-Indexe… | 1,94% | 27.325 SH | 02 Ekim 2026 | Günlük |
| UPGD · Invesco Exchange-Traded Fund Trust | 1,90% | 18.656 SH | 02 Ekim 2026 | Günlük |
| SPGP · Invesco Exchange-Traded Fund Trust | 1,86% | 323.409 SH | 02 Ekim 2026 | Günlük |
| IBB · iShares Trust | 1,81% | 1.512.762 SH | 11 Eylül 2026 | Günlük |
| HTEC · EXCHANGE TRADED CONCEPTS TRUST | 1,80% | 10.419 NS | 31 Temmuz 2026 | N-PORT |
| FXH · First Trust Exchange-Traded AlphaDE… | 1,78% | 156.306 NS | 31 Temmuz 2026 | N-PORT |
| RPG · Invesco Exchange-Traded Fund Trust | 1,63% | 270.969 SH | 02 Ekim 2026 | Günlük |
| IBBQ · Invesco Exchange-Traded Fund Trust … | 1,59% | 14.343 SH | 02 Ekim 2026 | Günlük |
| RSPH · Invesco Exchange-Traded Fund Trust | 1,54% | 114.153 SH | 02 Ekim 2026 | Günlük |
| BBP · ETFis Series Trust I | 1,52% | 12.506 NS | 31 Temmuz 2026 | N-PORT |
| CALF · Pacer Funds Trust | 1,52% | 465.439 NS | 31 Temmuz 2026 | N-PORT |
| GURU · Global X Funds | 1,37% | 7.010 NS | 31 Temmuz 2026 | N-PORT |
| QQQJ · Invesco Exchange-Traded Fund Trust … | 1,19% | 119.789 SH | 02 Ekim 2026 | Günlük |
| LSVD · ADVISORS' INNER CIRCLE FUND | 1,04% | 56.481 NS | 31 Temmuz 2026 | N-PORT |
| FTC · First Trust Exchange-Traded AlphaDE… | 1,03% | 113.368 NS | 31 Temmuz 2026 | N-PORT |
| SPVM · Invesco Exchange-Traded Fund Trust | 0,82% | 9.194 SH | 02 Ekim 2026 | Günlük |
| INFO · Harbor ETF Trust | 0,81% | 57.450 NS | 31 Temmuz 2026 | N-PORT |
| LSEQ · Harbor ETF Trust | 0,77% | 992 NS | 31 Temmuz 2026 | N-PORT |
| LABU · Direxion Shares ETF Trust | 0,77% | 32.018 NS | 31 Temmuz 2026 | N-PORT |
| JOET · Virtus ETF Trust II | 0,73% | 14.779 NS | 31 Temmuz 2026 | N-PORT |
| COWG · Pacer Funds Trust | 0,72% | 132.772 NS | 31 Temmuz 2026 | N-PORT |
| BRNY · EA Series Trust | 0,57% | 27.866 NS | 31 Temmuz 2026 | N-PORT |
| PDP · Invesco Exchange-Traded Fund Trust | 0,56% | 70.403 SH | 02 Ekim 2026 | Günlük |
| ESMV · iShares Trust | 0,54% | 339 SH | 11 Eylül 2026 | Günlük |
| VBK · VANGUARD INDEX FUNDS | 0,53% | 2.249.253 SH | 19 Ağustos 2026 | Günlük |
| FAD · First Trust Exchange-Traded AlphaDE… | 0,51% | 24.639 NS | 31 Temmuz 2026 | N-PORT |
| COWZ · Pacer Funds Trust | 0,50% | 774.539 NS | 31 Temmuz 2026 | N-PORT |
| ROUS · Lattice Strategies Trust | 0,49% | 29.166 NS | 31 Temmuz 2026 | N-PORT |
| HQGO · Lattice Strategies Trust | 0,49% | 2.011 NS | 31 Temmuz 2026 | N-PORT |
| TECB · iShares Trust | 0,49% | 19.516 SH | 11 Eylül 2026 | Günlük |
| VLLU · Harbor ETF Trust | 0,49% | 189 NS | 31 Temmuz 2026 | N-PORT |
| USMV · iShares Trust | 0,47% | 910.173 SH | 11 Eylül 2026 | Günlük |
| VFQY · VANGUARD WELLINGTON FUND | 0,46% | 19.147 SH | 19 Ağustos 2026 | Günlük |
| ESLV · Strategy Shares | 0,45% | 537 NS | 31 Temmuz 2026 | N-PORT |
| SDG · iShares Trust | 0,42% | 5.697 SH | 11 Eylül 2026 | Günlük |
| ACWV · iShares, Inc. | 0,41% | 111.137 SH | 11 Eylül 2026 | Günlük |
| JPME · J.P. Morgan Exchange-Traded Fund Tr… | 0,39% | 15.107 NS | 31 Temmuz 2026 | N-PORT |
| FEX · First Trust Exchange-Traded AlphaDE… | 0,38% | 49.720 NS | 31 Temmuz 2026 | N-PORT |
| FSMD · FIDELITY COVINGTON TRUST | 0,35% | 72.339 NS | 31 Temmuz 2026 | N-PORT |
| IYH · iShares Trust | 0,33% | 97.043 SH | 11 Eylül 2026 | Günlük |
| JPUS · J.P. Morgan Exchange-Traded Fund Tr… | 0,32% | 12.427 NS | 31 Temmuz 2026 | N-PORT |
| FHLC · FIDELITY COVINGTON TRUST | 0,29% | 80.584 NS | 31 Temmuz 2026 | N-PORT |
| VHT · VANGUARD WORLD FUND | 0,28% | 508.499 SH | 19 Ağustos 2026 | Günlük |
| VFMF · VANGUARD WELLINGTON FUND | 0,27% | 16.793 SH | 19 Ağustos 2026 | Günlük |
| IXJ · iShares Trust | 0,26% | 88.044 SH | 11 Eylül 2026 | Günlük |
| SIZE · iShares Trust | 0,25% | 8.715 SH | 11 Eylül 2026 | Günlük |
| FBUF · Fidelity Greenwood Street Trust | 0,25% | 498 NS | 31 Temmuz 2026 | N-PORT |
| VMAX · Lattice Strategies Trust | 0,24% | 997 NS | 31 Temmuz 2026 | N-PORT |
| LGDX · Tidal Trust III | 0,23% | 2.756 NS | 31 Temmuz 2026 | N-PORT |
| VB · VANGUARD INDEX FUNDS | 0,23% | 3.894.602 SH | 19 Ağustos 2026 | Günlük |
| CURE · Direxion Shares ETF Trust | 0,23% | 3.302 NS | 31 Temmuz 2026 | N-PORT |
| PWS · Pacer Funds Trust | 0,22% | 437 NS | 31 Temmuz 2026 | N-PORT |
| IWS · iShares Trust | 0,20% | 247.446 SH | 11 Eylül 2026 | Günlük |
| EUSA · iShares, Inc. | 0,20% | 30.370 SH | 11 Eylül 2026 | Günlük |
| RSP · Invesco Exchange-Traded Fund Trust | 0,19% | 1.548.872 SH | 02 Ekim 2026 | Günlük |
| FTLS · First Trust Exchange-Traded Fund III | 0,19% | 38.962 NS | 31 Temmuz 2026 | N-PORT |
| FHEQ · Fidelity Greenwood Street Trust | 0,18% | 13.826 NS | 31 Temmuz 2026 | N-PORT |
| IMCV · iShares Trust | 0,17% | 16.093 SH | 11 Eylül 2026 | Günlük |
| VFMO · VANGUARD WELLINGTON FUND | 0,17% | 30.550 SH | 19 Ağustos 2026 | Günlük |
| ESUM · Strategy Shares | 0,16% | 2.509 NS | 31 Temmuz 2026 | N-PORT |
| SPHQ · Invesco Exchange-Traded Fund Trust | 0,16% | 260.988 SH | 02 Ekim 2026 | Günlük |
| DFLV · Dimensional ETF Trust | 0,16% | 91.827 NS | 31 Temmuz 2026 | N-PORT |
| VFVA · VANGUARD WELLINGTON FUND | 0,16% | 12.315 SH | 19 Ağustos 2026 | Günlük |
| ESLG · Strategy Shares | 0,16% | 307 NS | 31 Temmuz 2026 | N-PORT |
| JQUA · J.P. Morgan Exchange-Traded Fund Tr… | 0,16% | 106.670 NS | 31 Temmuz 2026 | N-PORT |
| IWR · iShares Trust | 0,15% | 678.309 SH | 11 Eylül 2026 | Günlük |
| IMCB · iShares Trust | 0,14% | 19.540 SH | 11 Eylül 2026 | Günlük |
| EVUS · iShares Trust | 0,12% | 3.715 SH | 11 Eylül 2026 | Günlük |
| XOEF · iShares Trust | 0,12% | 213 SH | 11 Eylül 2026 | Günlük |
| IMCG · iShares Trust | 0,12% | 37.577 SH | 11 Eylül 2026 | Günlük |
| DFUV · Dimensional ETF Trust | 0,11% | 146.271 NS | 31 Temmuz 2026 | N-PORT |
| DFSU · Dimensional ETF Trust | 0,10% | 19.945 NS | 31 Temmuz 2026 | N-PORT |
| OMFL · Invesco Exchange-Traded Self-Indexe… | 0,10% | 41.885 SH | 02 Ekim 2026 | Günlük |
| ESGU · iShares Trust | 0,10% | 141.033 SH | 11 Eylül 2026 | Günlük |
| CATH · Global X Funds | 0,10% | 10.371 NS | 31 Temmuz 2026 | N-PORT |
| SPMO · Invesco Exchange-Traded Fund Trust … | 0,09% | 180.160 SH | 02 Ekim 2026 | Günlük |
| DXUV · Dimensional ETF Trust | 0,09% | 4.162 NS | 31 Temmuz 2026 | N-PORT |
| EQAL · Invesco Exchange-Traded Fund Trust … | 0,09% | 6.132 SH | 02 Ekim 2026 | Günlük |
| USXF · iShares Trust | 0,08% | 10.050 SH | 11 Eylül 2026 | Günlük |
| PALC · Pacer Funds Trust | 0,08% | 1.398 NS | 31 Temmuz 2026 | N-PORT |
| DCOR · Dimensional ETF Trust | 0,08% | 21.901 NS | 31 Temmuz 2026 | N-PORT |
| DFAC · Dimensional ETF Trust | 0,07% | 298.392 NS | 31 Temmuz 2026 | N-PORT |
| GARP · iShares Trust | 0,07% | 17.562 SH | 11 Eylül 2026 | Günlük |
| SUSL · iShares Trust | 0,06% | 6.008 SH | 11 Eylül 2026 | Günlük |
| CHRI · Global X Funds | 0,06% | 41 NS | 31 Temmuz 2026 | N-PORT |
| DSI · iShares Trust | 0,06% | 25.952 SH | 11 Eylül 2026 | Günlük |
| IVW · iShares Trust | 0,06% | 354.438 SH | 11 Eylül 2026 | Günlük |
| IUSG · iShares Trust | 0,06% | 147.395 SH | 11 Eylül 2026 | Günlük |
| IWD · iShares Trust | 0,05% | 367.740 SH | 11 Eylül 2026 | Günlük |
| GLOF · iShares Trust | 0,05% | 840 SH | 11 Eylül 2026 | Günlük |
| VOOG · VANGUARD ADMIRAL FUNDS | 0,05% | 124.582 SH | 19 Ağustos 2026 | Günlük |
| VONV · VANGUARD SCOTTSDALE FUNDS | 0,05% | 100.000 SH | 19 Ağustos 2026 | Günlük |
| REVS · Columbia ETF Trust I | 0,05% | 1.396 NS | 31 Temmuz 2026 | N-PORT |
| EGLE · Global X Funds | 0,05% | 9 NS | 31 Temmuz 2026 | N-PORT |
| HAPI · Harbor ETF Trust | 0,05% | 1.975 NS | 31 Temmuz 2026 | N-PORT |
| PRF · Invesco Exchange-Traded Fund Trust | 0,05% | 38.893 SH | 02 Ekim 2026 | Günlük |
| DFVX · Dimensional ETF Trust | 0,05% | 1.993 NS | 31 Temmuz 2026 | N-PORT |
| IUS · Invesco Exchange-Traded Self-Indexe… | 0,04% | 3.572 SH | 02 Ekim 2026 | Günlük |
| DFAU · Dimensional ETF Trust | 0,04% | 43.168 NS | 31 Temmuz 2026 | N-PORT |
| TOV · EA Series Trust | 0,04% | 910 NS | 31 Temmuz 2026 | N-PORT |
| TOPC · iShares Trust | 0,04% | 100 SH | 11 Eylül 2026 | Günlük |
| ILCV · iShares Trust | 0,04% | 3.819 SH | 11 Eylül 2026 | Günlük |
| XVV · iShares Trust | 0,04% | 1.907 SH | 11 Eylül 2026 | Günlük |
| XYLG · Global X Funds | 0,03% | 186 NS | 31 Temmuz 2026 | N-PORT |
| XCLR · Global X Funds | 0,03% | 10 NS | 31 Temmuz 2026 | N-PORT |
| XRMI · Global X Funds | 0,03% | 133 NS | 31 Temmuz 2026 | N-PORT |
| IVV · iShares Trust | 0,03% | 2.115.770 SH | 11 Eylül 2026 | Günlük |
| XYLD · Global X Funds | 0,03% | 8.564 NS | 31 Temmuz 2026 | N-PORT |
| QVML · Invesco Exchange-Traded Fund Trust … | 0,03% | 4.458 SH | 02 Ekim 2026 | Günlük |
| PTLC · Pacer Funds Trust | 0,03% | 8.472 NS | 31 Temmuz 2026 | N-PORT |
| ILCB · iShares Trust | 0,03% | 3.242 SH | 11 Eylül 2026 | Günlük |
| BBUS · J.P. Morgan Exchange-Traded Fund Tr… | 0,03% | 22.989 NS | 31 Temmuz 2026 | N-PORT |
| VOTE · TCW ETF Trust | 0,03% | 2.822 NS | 31 Temmuz 2026 | N-PORT |
| PBP · Invesco Exchange-Traded Fund Trust | 0,03% | 1.013 SH | 02 Ekim 2026 | Günlük |
| BKLC · BNY Mellon ETF Trust | 0,03% | 13.892 NS | 31 Temmuz 2026 | N-PORT |
| PBUS · Invesco Exchange-Traded Fund Trust … | 0,03% | 29.419 SH | 02 Ekim 2026 | Günlük |
| VOO · VANGUARD INDEX FUNDS | 0,03% | 4.357.457 SH | 19 Ağustos 2026 | Günlük |
| VTI · VANGUARD INDEX FUNDS | 0,03% | 5.391.866 SH | 19 Ağustos 2026 | Günlük |
| VONE · VANGUARD SCOTTSDALE FUNDS | 0,03% | 27.427 SH | 19 Ağustos 2026 | Günlük |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0,03% | 13.959 SH | 19 Ağustos 2026 | Günlük |
| ESGV · VANGUARD WORLD FUND | 0,03% | 37.474 SH | 19 Ağustos 2026 | Günlük |
| DFUS · Dimensional ETF Trust | 0,03% | 51.979 NS | 31 Temmuz 2026 | N-PORT |
| XTR · Global X Funds | 0,03% | 12 NS | 31 Temmuz 2026 | N-PORT |
| IWB · iShares Trust | 0,03% | 114.458 SH | 11 Eylül 2026 | Günlük |
| IYY · iShares Trust | 0,03% | 7.092 SH | 11 Eylül 2026 | Günlük |
| SPUU · Direxion Shares ETF Trust | 0,03% | 634 NS | 31 Temmuz 2026 | N-PORT |
| QDPL · Pacer Funds Trust | 0,03% | 4.037 NS | 31 Temmuz 2026 | N-PORT |
| DYNF · BlackRock ETF Trust | 0,03% | 95.298 SH | 11 Eylül 2026 | Günlük |
| IWV · iShares Trust | 0,03% | 45.601 SH | 11 Eylül 2026 | Günlük |
| ITOT · iShares Trust | 0,03% | 215.857 SH | 11 Eylül 2026 | Günlük |
| RWL · Invesco Exchange-Traded Fund Trust … | 0,03% | 23.005 SH | 02 Ekim 2026 | Günlük |
| ACVF · ETF Opportunities Trust | 0,03% | 345 NS | 31 Temmuz 2026 | N-PORT |
| RECS · Columbia ETF Trust I | 0,03% | 13.186 NS | 31 Temmuz 2026 | N-PORT |
| ILCG · iShares Trust | 0,03% | 6.647 SH | 11 Eylül 2026 | Günlük |
| PHDG · Invesco Actively Managed Exchange-T… | 0,03% | 133 SH | 02 Ekim 2026 | Günlük |
| TOK · iShares Trust | 0,03% | 485 SH | 11 Eylül 2026 | Günlük |
| TILT · FlexShares Trust | 0,03% | 4.582 NS | 31 Temmuz 2026 | N-PORT |
| HCMT · Direxion Shares ETF Trust | 0,02% | 1.167 NS | 31 Temmuz 2026 | N-PORT |
| SPXL · Direxion Shares ETF Trust | 0,02% | 13.118 NS | 31 Temmuz 2026 | N-PORT |
| URTH · iShares, Inc. | 0,02% | 14.482 SH | 11 Eylül 2026 | Günlük |
| ACWI · iShares Trust | 0,02% | 55.495 SH | 11 Eylül 2026 | Günlük |
| VT · VANGUARD INTERNATIONAL EQUITY INDEX… | 0,02% | 142.324 SH | 19 Ağustos 2026 | Günlük |
| CRBN · iShares Trust | 0,01% | 876 SH | 11 Eylül 2026 | Günlük |
INCY Analist Uzlaşması Boğa ve ayı analist görüşleri, 12 aylık fiyat hedefi, yukarı yönlü potansiyel
derecelendirme · 35 analist
AL
Medyan hedef
$130.00
+13,9%
8 22,9%
Güçlü Al
10 28,6%
Al
17 48,6%
Tut
0 0,0%
Sat
0 0,0%
Güçlü Sat
12 Aylık Fiyat Hedefi
23 analist · 2026-09-29Ortalama hedef $127.96 +12,1%
Şimdi
Mevcut fiyat $114.13
Düşük$86.00
Ortalama$127.96
Yüksek$155.00
Akran karşılaştırması (GICS alt sektörü) Anahtar metrikler sektördeki benzerlerine karşı
Mali yıl bazında, fiyatlar her şirketin son mali yıl kapanışına göredir.
| Hisse Sembolü | Piyasa Değeri | P/E | Gelir YoY | Net Kar Marjı | ROE | Brüt Kar Marjı |
|---|---|---|---|---|---|---|
| INCY | $19.60B | 15.4 | 21.2% | 25.0% | 27.6% | · |
| RVMD | · | · | · | · | · | · |
| BIIB | $25.84B | 20.0 | 2.2% | 13.1% | 7.2% | · |
| ALNY | $52.64B | 170.7 | 65.2% | 8.5% | 60.4% | · |
| UTHR | $21.27B | 17.5 | 10.6% | 41.9% | 18.7% | 87.9% |
| INSM | $37.29B | -27.1 | 66.7% | -210.5% | -128.4% | · |
| NBIX | $14.20B | 30.4 | 21.4% | 16.7% | 16.1% | · |
| EXEL | $11.44B | 15.7 | 7.0% | 33.7% | 37.3% | · |
| SMMT | $13.56B | -12.1 | · | · | -235.1% | · |
| TWST | $1.71B | -21.6 | 20.3% | -20.6% | -17.0% | · |
Son Haberler Bu şirketten bahseden son manşetler
İşlem Sinyalleri Giriş fiyatı ve risk/ödül oranı ile son alım/satım sinyalleri
BLUECHIP_DIP
Zarar durduruldu
risk 1
ödül 5,00
giriş
$95.85
R:R 5,00
BLUECHIP_DIP
Süresi Doldu
risk 1
ödül 5,00
giriş
$95.27
R:R 5,00
BLUECHIP_DIP
Süresi Doldu
risk 1
ödül 1,30
giriş
$91.77
R:R 1,30
Şu anda açık sinyal yok — hiçbir kart dolu değil ve bu dürüstçe.
Metriklerim Kişisel izleme listeniz — Tam Temeller'den seçilen satırlar
Sizin için önemli olan metrikleri seçin — Yukarıdaki Tam Temeller bölümündeki herhangi bir satırın yanındaki + işaretine tıklayın.
Seçiminiz kaydedildi ve tüm hisse senetlerinde sizinle birlikte gelir.
Kaynak: SEC 10-Q dosyalandı Tem 28, 2026